Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Operations (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Cash from Operations for 7 consecutive years, with 56420000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 71.11% to 56420000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 445910000.0 through Dec 2025, up 14.37% year-over-year, with the annual reading at 445910000.0 for FY2025, 14.37% up from the prior year.
  • Cash from Operations hit 56420000.0 in Q4 2025 for BridgeBio Pharma, up from 109574000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 74703000.0 in Q2 2024 to a low of 219537000.0 in Q1 2024.
  • Historically, Cash from Operations has averaged 120589200.0 across 5 years, with a median of 129357000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: crashed 272.22% in 2023 and later soared 165.9% in 2024.
  • Year by year, Cash from Operations stood at 133895000.0 in 2021, then surged by 30.36% to 93243000.0 in 2022, then crashed by 33.86% to 124819000.0 in 2023, then crashed by 56.49% to 195326000.0 in 2024, then soared by 71.11% to 56420000.0 in 2025.
  • Business Quant data shows Cash from Operations for BBIO at 56420000.0 in Q4 2025, 109574000.0 in Q3 2025, and 80681000.0 in Q2 2025.